JP2010521522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010521522A5 JP2010521522A5 JP2009554036A JP2009554036A JP2010521522A5 JP 2010521522 A5 JP2010521522 A5 JP 2010521522A5 JP 2009554036 A JP2009554036 A JP 2009554036A JP 2009554036 A JP2009554036 A JP 2009554036A JP 2010521522 A5 JP2010521522 A5 JP 2010521522A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazolo
- pyridine
- optionally substituted
- dione
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 1,3-Benzothiazol-2-yl Chemical group 0.000 claims description 71
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 125000001072 heteroaryl group Chemical group 0.000 claims description 30
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 26
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 21
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 18
- 125000003342 alkenyl group Chemical group 0.000 claims description 18
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 18
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 16
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 15
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 15
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 9
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000005024 alkenyl aryl group Chemical group 0.000 claims description 5
- 150000005229 pyrazolopyridines Chemical class 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 5
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- YGXAYPWLSCJZRQ-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(2-methoxyethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CC=C2SC(N3NC4=CC(=O)N(CCOC)C(=C4C3=O)CC)=NC2=C1 YGXAYPWLSCJZRQ-UHFFFAOYSA-N 0.000 claims 2
- WVGSMJYPLAOVRV-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(3-morpholin-4-ylpropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(CC)N1CCCN1CCOCC1 WVGSMJYPLAOVRV-UHFFFAOYSA-N 0.000 claims 2
- NZTATZGYYCOWNR-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(4-methylpiperazin-1-yl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(CC)N1N1CCN(C)CC1 NZTATZGYYCOWNR-UHFFFAOYSA-N 0.000 claims 2
- SIXSWBRHHWBRRQ-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-ethyl-5-(pyridin-2-ylmethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(CC)N1CC1=CC=CC=N1 SIXSWBRHHWBRRQ-UHFFFAOYSA-N 0.000 claims 2
- SDCAMLQHQRVVAN-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-methyl-5-(oxolan-2-ylmethyl)-1-(pyridin-2-ylmethyl)pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2N(CC=3N=CC=CC=3)N(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CC1CCCO1 SDCAMLQHQRVVAN-UHFFFAOYSA-N 0.000 claims 2
- DNKYHHFCPXKFIY-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-methyl-5-(pyridin-2-ylmethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(C)N1CC1=CC=CC=N1 DNKYHHFCPXKFIY-UHFFFAOYSA-N 0.000 claims 2
- SOWDNLOMIQWAKK-UHFFFAOYSA-N 4-ethyl-2-(4-fluorophenyl)-5-(2-methoxyethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(CC)N(CCOC)C(=O)C=C2NN1C1=CC=C(F)C=C1 SOWDNLOMIQWAKK-UHFFFAOYSA-N 0.000 claims 2
- STQHYZIEXCJXHE-UHFFFAOYSA-N 4-ethyl-2-(4-fluorophenyl)-5-(2-phenylethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(F)=CC=3)C(=O)C2=C(CC)N1CCC1=CC=CC=C1 STQHYZIEXCJXHE-UHFFFAOYSA-N 0.000 claims 2
- DKRLZUYJVLRNKH-UHFFFAOYSA-N 4-ethyl-2-(4-fluorophenyl)-5-(3-morpholin-4-ylpropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(F)=CC=3)C(=O)C2=C(CC)N1CCCN1CCOCC1 DKRLZUYJVLRNKH-UHFFFAOYSA-N 0.000 claims 2
- SVWXTWPIDMRQBZ-UHFFFAOYSA-N 4-ethyl-2-(4-fluorophenyl)-5-(pyridin-2-ylmethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(F)=CC=3)C(=O)C2=C(CC)N1CC1=CC=CC=N1 SVWXTWPIDMRQBZ-UHFFFAOYSA-N 0.000 claims 2
- JTHHUSZXKAATHK-UHFFFAOYSA-N 4-ethyl-2-(4-fluorophenyl)-5-morpholin-4-yl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(F)=CC=3)C(=O)C2=C(CC)N1N1CCOCC1 JTHHUSZXKAATHK-UHFFFAOYSA-N 0.000 claims 2
- HKCHGZRTXYMUOB-UHFFFAOYSA-N 4-ethyl-5-(3-morpholin-4-ylpropyl)-2-[4-(trifluoromethoxy)phenyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(OC(F)(F)F)=CC=3)C(=O)C2=C(CC)N1CCCN1CCOCC1 HKCHGZRTXYMUOB-UHFFFAOYSA-N 0.000 claims 2
- JHESKYYOWZPHPU-UHFFFAOYSA-N 4-ethyl-5-(3-morpholin-4-ylpropyl)-2-[4-(trifluoromethyl)phenyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(=CC=3)C(F)(F)F)C(=O)C2=C(CC)N1CCCN1CCOCC1 JHESKYYOWZPHPU-UHFFFAOYSA-N 0.000 claims 2
- GDXIFMQUTARHDA-UHFFFAOYSA-N 4-methyl-2-(2-methylphenyl)-5-(3-morpholin-4-ylpropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound CC1=CC=CC=C1N1C(=O)C2=C(C)N(CCCN3CCOCC3)C(=O)C=C2N1 GDXIFMQUTARHDA-UHFFFAOYSA-N 0.000 claims 2
- DTMJLSYMVBVNOW-UHFFFAOYSA-N 5-(2-morpholin-4-ylethyl)-2-pyridin-2-yl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=C2C(=O)N(C=3N=CC=CC=3)NC2=CC(=O)N1CCN1CCOCC1 DTMJLSYMVBVNOW-UHFFFAOYSA-N 0.000 claims 2
- RYPVHNJGJGSXHH-UHFFFAOYSA-N 5-benzyl-4-ethyl-2-(4-fluorophenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(F)=CC=3)C(=O)C2=C(CC)N1CC1=CC=CC=C1 RYPVHNJGJGSXHH-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- OPWIRJKWKBGRBM-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-4-methyl-5-[3-(2-oxopyrrolidin-1-yl)propyl]-2-phenylpyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2N(CC=3C(=CC=CC=3)Cl)N(C=3C=CC=CC=3)C(=O)C2=C(C)N1CCCN1CCCC1=O OPWIRJKWKBGRBM-UHFFFAOYSA-N 0.000 claims 1
- RQLIJUQDJIWPSW-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-[2-(1h-imidazol-5-yl)ethyl]-4-methyl-2-phenylpyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2N(CC=3C=CC(Cl)=CC=3)N(C=3C=CC=CC=3)C(=O)C2=C(C)N1CCC1=CN=CN1 RQLIJUQDJIWPSW-UHFFFAOYSA-N 0.000 claims 1
- GQGQOPNIMHBAOH-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-5-[2-(1h-indol-3-yl)ethyl]-4-methyl-2-phenylpyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C=CC=CC=1N1C(=O)C2=C(C)N(CCC=3C4=CC=CC=C4NC=3)C(=O)C=C2N1CC1=CC=C(F)C=C1 GQGQOPNIMHBAOH-UHFFFAOYSA-N 0.000 claims 1
- FDPVGRGPQDYSEQ-UHFFFAOYSA-N 2,4-diphenyl-5-(pyridin-3-ylmethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C=1C=CC=CC=1C1=C2C(=O)N(C=3C=CC=CC=3)NC2=CC(=O)N1CC1=CC=CN=C1 FDPVGRGPQDYSEQ-UHFFFAOYSA-N 0.000 claims 1
- HAUIRJQRGRMAIV-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-1-[(2-chlorophenyl)methyl]-4-methyl-5-(3-morpholin-4-ylpropyl)pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2N(CC=3C(=CC=CC=3)Cl)N(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CCCN1CCOCC1 HAUIRJQRGRMAIV-UHFFFAOYSA-N 0.000 claims 1
- XHGZXAVUEWBNHE-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-1-[(2-chlorophenyl)methyl]-4-methyl-5-morpholin-4-ylpyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2N(CC=3C(=CC=CC=3)Cl)N(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1N1CCOCC1 XHGZXAVUEWBNHE-UHFFFAOYSA-N 0.000 claims 1
- RYDRQKFTQARJHP-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-1-[(4-bromophenyl)methyl]-4-methyl-5-(2-morpholin-4-ylethyl)pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2N(CC=3C=CC(Br)=CC=3)N(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CCN1CCOCC1 RYDRQKFTQARJHP-UHFFFAOYSA-N 0.000 claims 1
- VDGVQFKQALNCIZ-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-1-[(4-fluorophenyl)methyl]-4-methyl-5-(3-morpholin-4-ylpropyl)pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2N(CC=3C=CC(F)=CC=3)N(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CCCN1CCOCC1 VDGVQFKQALNCIZ-UHFFFAOYSA-N 0.000 claims 1
- XYRKERQLRYSNDV-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-1-benzyl-4-methyl-5-(oxolan-2-ylmethyl)pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2N(CC=3C=CC=CC=3)N(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CC1CCCO1 XYRKERQLRYSNDV-UHFFFAOYSA-N 0.000 claims 1
- HSSPTKKINZIHTL-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-1-benzyl-5-(furan-2-ylmethyl)-4-methylpyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2N(CC=3C=CC=CC=3)N(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CC1=CC=CO1 HSSPTKKINZIHTL-UHFFFAOYSA-N 0.000 claims 1
- QALRXLQBQWGLSW-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-ethyl-5-[1-[(4-methylphenyl)methyl]piperidin-4-yl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(CC)N1C(CC1)CCN1CC1=CC=C(C)C=C1 QALRXLQBQWGLSW-UHFFFAOYSA-N 0.000 claims 1
- GDODCCPBPFSXIK-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-methyl-1-[(3-methylphenyl)methyl]-5-(3-morpholin-4-ylpropyl)pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound CC1=CC=CC(CN2C3=CC(=O)N(CCCN4CCOCC4)C(C)=C3C(=O)N2C=2SC3=CC=CC=C3N=2)=C1 GDODCCPBPFSXIK-UHFFFAOYSA-N 0.000 claims 1
- SDYDERKEOSPKDV-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-methyl-1-[(4-methylphenyl)methyl]-5-(3-morpholin-4-ylpropyl)pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CC(C)=CC=C1CN1C2=CC(=O)N(CCCN3CCOCC3)C(C)=C2C(=O)N1C1=NC2=CC=CC=C2S1 SDYDERKEOSPKDV-UHFFFAOYSA-N 0.000 claims 1
- YZVZFGKBBHGZOI-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-methyl-5-(2-methylbutyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CC=C2SC(N3NC=4C(C3=O)=C(C)N(C(C=4)=O)CC(C)CC)=NC2=C1 YZVZFGKBBHGZOI-UHFFFAOYSA-N 0.000 claims 1
- CWLBYWBQCRLXAZ-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-methyl-5-(2-phenylethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CCC1=CC=CC=C1 CWLBYWBQCRLXAZ-UHFFFAOYSA-N 0.000 claims 1
- QMJQNCDSPCPHQO-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-methyl-5-(3-morpholin-4-ylpropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CCCN1CCOCC1 QMJQNCDSPCPHQO-UHFFFAOYSA-N 0.000 claims 1
- WUKFZNWYWGZKRP-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-4-methyl-5-morpholin-4-yl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1N1CCOCC1 WUKFZNWYWGZKRP-UHFFFAOYSA-N 0.000 claims 1
- PLLXXGHEDZWKGG-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-5-[2-(1h-imidazol-5-yl)ethyl]-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CCC1=CN=CN1 PLLXXGHEDZWKGG-UHFFFAOYSA-N 0.000 claims 1
- BMWFXSPRYOHMMZ-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-5-[2-(1h-indol-3-yl)ethyl]-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CC=C2SC(N3NC4=CC(=O)N(CCC=5C6=CC=CC=C6NC=5)C(=C4C3=O)C)=NC2=C1 BMWFXSPRYOHMMZ-UHFFFAOYSA-N 0.000 claims 1
- PWDYNBQZRITTAZ-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-5-[2-(4-hexanoylpiperazin-1-yl)ethyl]-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C(=O)CCCCC)CCN1CCN1C(=O)C=C(NN(C=2SC3=CC=CC=C3N=2)C2=O)C2=C1C PWDYNBQZRITTAZ-UHFFFAOYSA-N 0.000 claims 1
- KJYCIPWGCPJWMD-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)-5-[2-(4-methoxyphenyl)ethyl]-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CC(OC)=CC=C1CCN1C(=O)C=C(NN(C=2SC3=CC=CC=C3N=2)C2=O)C2=C1C KJYCIPWGCPJWMD-UHFFFAOYSA-N 0.000 claims 1
- CYIITHFCXXBOEQ-UHFFFAOYSA-N 2-(2,5-difluorophenyl)-4-ethyl-5-(3-morpholin-4-ylpropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=C(F)C=3)F)C(=O)C2=C(CC)N1CCCN1CCOCC1 CYIITHFCXXBOEQ-UHFFFAOYSA-N 0.000 claims 1
- WLTPZDWPBFJKEF-UHFFFAOYSA-N 2-(2-chlorophenyl)-4-ethyl-5-(pyridin-3-ylmethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C(CC)N1CC1=CC=CN=C1 WLTPZDWPBFJKEF-UHFFFAOYSA-N 0.000 claims 1
- UFSBBXSERZQNHQ-UHFFFAOYSA-N 4-[[2-(1,3-benzothiazol-2-yl)-4-methyl-3,6-dioxo-1h-pyrazolo[4,3-c]pyridin-5-yl]methyl]benzoic acid Chemical compound O=C1C=C2NN(C=3SC4=CC=CC=C4N=3)C(=O)C2=C(C)N1CC1=CC=C(C(O)=O)C=C1 UFSBBXSERZQNHQ-UHFFFAOYSA-N 0.000 claims 1
- SCPLVJAUOOAQQS-UHFFFAOYSA-N 4-ethyl-2-(2-methoxyphenyl)-5-(3-morpholin-4-ylpropyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C(=CC=CC=3)OC)C(=O)C2=C(CC)N1CCCN1CCOCC1 SCPLVJAUOOAQQS-UHFFFAOYSA-N 0.000 claims 1
- MOCCDBAWHYEHAG-UHFFFAOYSA-N 4-ethyl-5-morpholin-4-yl-2-phenyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC=CC=3)C(=O)C2=C(CC)N1N1CCOCC1 MOCCDBAWHYEHAG-UHFFFAOYSA-N 0.000 claims 1
- FJPUXMVNLPHRCZ-UHFFFAOYSA-N 4-methyl-2-(2-methylphenyl)-5-(pyridin-2-ylmethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound CC1=CC=CC=C1N1C(=O)C2=C(C)N(CC=3N=CC=CC=3)C(=O)C=C2N1 FJPUXMVNLPHRCZ-UHFFFAOYSA-N 0.000 claims 1
- ICYYTFBMNVALJS-UHFFFAOYSA-N 4-methyl-2-phenyl-5-(2-phenylethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC=CC=3)C(=O)C2=C(C)N1CCC1=CC=CC=C1 ICYYTFBMNVALJS-UHFFFAOYSA-N 0.000 claims 1
- ISLQXEIRVZXLJA-UHFFFAOYSA-N 4-methyl-2-phenyl-5-(pyridin-3-ylmethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC=CC=3)C(=O)C2=C(C)N1CC1=CC=CN=C1 ISLQXEIRVZXLJA-UHFFFAOYSA-N 0.000 claims 1
- KQWPBXREZDLGMX-UHFFFAOYSA-N 4-methyl-2-phenyl-5-(thiophen-2-ylmethyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC=CC=3)C(=O)C2=C(C)N1CC1=CC=CS1 KQWPBXREZDLGMX-UHFFFAOYSA-N 0.000 claims 1
- JNUCVMRXTBMHRQ-UHFFFAOYSA-N 4-methyl-5-(2-morpholin-4-ylethyl)-2-phenyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC=CC=3)C(=O)C2=C(C)N1CCN1CCOCC1 JNUCVMRXTBMHRQ-UHFFFAOYSA-N 0.000 claims 1
- IXQAPEWDNTZIAO-UHFFFAOYSA-N 4-methyl-5-(oxolan-2-ylmethyl)-2-phenyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC=CC=3)C(=O)C2=C(C)N1CC1CCCO1 IXQAPEWDNTZIAO-UHFFFAOYSA-N 0.000 claims 1
- QAABOTJXRMFONY-UHFFFAOYSA-N 4-methyl-5-morpholin-4-yl-2-phenyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC=CC=3)C(=O)C2=C(C)N1N1CCOCC1 QAABOTJXRMFONY-UHFFFAOYSA-N 0.000 claims 1
- ANUFFQUQIIVNIW-UHFFFAOYSA-N 5-(1,3-benzodioxol-5-ylmethyl)-4-methyl-2-phenyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(CC=3C=C4OCOC4=CC=3)C(=O)C=C2NN1C1=CC=CC=C1 ANUFFQUQIIVNIW-UHFFFAOYSA-N 0.000 claims 1
- MIRFIMNUTDFIPW-UHFFFAOYSA-N 5-(furan-2-ylmethyl)-4-methyl-2-phenyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC=CC=3)C(=O)C2=C(C)N1CC1=CC=CO1 MIRFIMNUTDFIPW-UHFFFAOYSA-N 0.000 claims 1
- FUQPUNMXZOQPSS-UHFFFAOYSA-N 5-[2-(1h-indol-3-yl)ethyl]-4-methyl-1-[(3-methylphenyl)methyl]-2-phenylpyrazolo[4,3-c]pyridine-3,6-dione Chemical compound CC1=CC=CC(CN2C3=CC(=O)N(CCC=4C5=CC=CC=C5NC=4)C(C)=C3C(=O)N2C=2C=CC=CC=2)=C1 FUQPUNMXZOQPSS-UHFFFAOYSA-N 0.000 claims 1
- ZRJNMDXRJSUJDE-UHFFFAOYSA-N 5-[2-(1h-indol-3-yl)ethyl]-4-methyl-2-phenyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C2=C(C)N(CCC=3C4=CC=CC=C4NC=3)C(=O)C=C2NN1C1=CC=CC=C1 ZRJNMDXRJSUJDE-UHFFFAOYSA-N 0.000 claims 1
- KSOBUYBTZNHWAB-UHFFFAOYSA-N 5-[2-(4-acetylpiperazin-1-yl)ethyl]-2-(1,3-benzothiazol-2-yl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1CN(C(=O)C)CCN1CCN1C(=O)C=C(NN(C=2SC3=CC=CC=C3N=2)C2=O)C2=C1C KSOBUYBTZNHWAB-UHFFFAOYSA-N 0.000 claims 1
- AERIONKKSUDYPZ-UHFFFAOYSA-N 5-benzyl-2-(4-fluorophenyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(F)=CC=3)C(=O)C2=C(C)N1CC1=CC=CC=C1 AERIONKKSUDYPZ-UHFFFAOYSA-N 0.000 claims 1
- ANKFMCUMWMEHBE-UHFFFAOYSA-N 5-benzyl-2-(4-methoxyphenyl)-4-methyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CC(OC)=CC=C1N1C(=O)C2=C(C)N(CC=3C=CC=CC=3)C(=O)C=C2N1 ANKFMCUMWMEHBE-UHFFFAOYSA-N 0.000 claims 1
- ZMSQJBSJAFLATO-UHFFFAOYSA-N 5-benzyl-4-methyl-2-(4-nitrophenyl)-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC(=CC=3)[N+]([O-])=O)C(=O)C2=C(C)N1CC1=CC=CC=C1 ZMSQJBSJAFLATO-UHFFFAOYSA-N 0.000 claims 1
- YSUAHWBNDNZDME-UHFFFAOYSA-N 5-benzyl-4-methyl-2-phenyl-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound O=C1C=C2NN(C=3C=CC=CC=3)C(=O)C2=C(C)N1CC1=CC=CC=C1 YSUAHWBNDNZDME-UHFFFAOYSA-N 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010007749 Cataract diabetic Diseases 0.000 claims 1
- 206010011903 Deafness traumatic Diseases 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- 208000002946 Noise-Induced Hearing Loss Diseases 0.000 claims 1
- 206010033109 Ototoxicity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010036346 Posterior capsule opacification Diseases 0.000 claims 1
- 206010036626 Presbyacusis Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000007025 diabetic cataract Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002664 drug-induced hearing loss Diseases 0.000 claims 1
- 210000003027 ear inner Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000002008 hemorrhagic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002314 neuroinflammatory effect Effects 0.000 claims 1
- 231100000262 ototoxicity Toxicity 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 230000001720 vestibular Effects 0.000 claims 1
- 125000005015 aryl alkynyl group Chemical group 0.000 description 10
- 125000005312 heteroarylalkynyl group Chemical group 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- GCJYUUCHJZQFLE-JQWIXIFHSA-N (2s)-2-[[2-[[(2s)-2-aminopropanoyl]amino]acetyl]amino]-n-[2-[2-(1h-imidazol-5-yl)ethylamino]acetyl]pentanediamide Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NC(=O)CNCCC1=CN=CN1 GCJYUUCHJZQFLE-JQWIXIFHSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- ONQBOTKLCMXPOF-UHFFFAOYSA-N 1-ethylpyrrolidine Chemical compound CCN1CCCC1 ONQBOTKLCMXPOF-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 125000006076 2-ethyl-1-butenyl group Chemical group 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005354 acylalkyl group Chemical group 0.000 description 1
- 125000004945 acylaminoalkyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005217 alkenylheteroaryl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical group 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- PJMICNUGBHGMKQ-UHFFFAOYSA-N ethane-1,1,2-triamine Chemical class NCC(N)N PJMICNUGBHGMKQ-UHFFFAOYSA-N 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000005990 isobenzothienyl group Chemical group 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 108010035114 procamine Proteins 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 125000004963 sulfonylalkyl group Chemical group 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89628407P | 2007-03-22 | 2007-03-22 | |
| US60/896,284 | 2007-03-22 | ||
| EP07109555.8 | 2007-06-04 | ||
| EP07109555A EP2002835A1 (en) | 2007-06-04 | 2007-06-04 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| PCT/EP2008/053390 WO2008113856A1 (en) | 2007-03-22 | 2008-03-20 | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015050104A Division JP6047189B2 (ja) | 2007-03-22 | 2015-03-13 | Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体を含有する医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010521522A JP2010521522A (ja) | 2010-06-24 |
| JP2010521522A5 true JP2010521522A5 (enExample) | 2013-08-08 |
| JP5715340B2 JP5715340B2 (ja) | 2015-05-07 |
Family
ID=38653574
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554036A Active JP5715340B2 (ja) | 2007-03-22 | 2008-03-20 | Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体 |
| JP2015050104A Active JP6047189B2 (ja) | 2007-03-22 | 2015-03-13 | Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体を含有する医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015050104A Active JP6047189B2 (ja) | 2007-03-22 | 2015-03-13 | Ｎａｄｐｈオキシダーゼインヒビターとしてのピラゾロピリジン誘導体を含有する医薬組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8389518B2 (enExample) |
| EP (3) | EP2002835A1 (enExample) |
| JP (2) | JP5715340B2 (enExample) |
| CN (2) | CN101686967B (enExample) |
| AU (1) | AU2008228186C1 (enExample) |
| BR (1) | BRPI0808824B8 (enExample) |
| CA (1) | CA2676954C (enExample) |
| CY (2) | CY1113556T1 (enExample) |
| DK (2) | DK2139477T3 (enExample) |
| ES (2) | ES2512491T3 (enExample) |
| HR (2) | HRP20130143T1 (enExample) |
| IL (1) | IL201009A (enExample) |
| PL (2) | PL2545918T3 (enExample) |
| PT (2) | PT2545918E (enExample) |
| RS (2) | RS53641B1 (enExample) |
| SI (2) | SI2139477T1 (enExample) |
| WO (1) | WO2008113856A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2000176A1 (en) | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
| EP2166010A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2165707A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166008A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| US20120141461A1 (en) * | 2009-07-17 | 2012-06-07 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating fibrotic disorders |
| EP2305679A1 (en) * | 2009-09-28 | 2011-04-06 | GenKyoTex SA | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| EP2512242B8 (en) * | 2009-12-18 | 2015-12-09 | GlaxoSmithKline Intellectual Property Limited | Novel compounds |
| EP2361912A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| EP2361911A1 (en) * | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| US9428478B2 (en) | 2011-06-13 | 2016-08-30 | Emory University | Piperazine derivatives, compositions, and uses related thereto |
| GB2494679A (en) * | 2011-09-15 | 2013-03-20 | Univ Jw Goethe Frankfurt Main | Treatment of neuropathic pain and nerve injury by Nox4 inhibition |
| EP2591782A1 (en) * | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
| US9688960B2 (en) | 2013-03-14 | 2017-06-27 | Eastern Virginia Medical School | Methods of preserving and protecting pancreatic beta cells and treating or preventing diabetes by inhibiting NOX-1 |
| EP2857399A1 (en) | 2013-10-03 | 2015-04-08 | GenKyoTex SA | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction |
| EP3098220A1 (en) | 2015-05-28 | 2016-11-30 | GenKyoTex SA | Process for the preparation of a nadph oxidase inhibitor and its polymorphs and uses thereof |
| CN107743483B (zh) * | 2015-06-22 | 2022-01-28 | 埃科特莱茵药品有限公司 | Nadph氧化酶4抑制剂 |
| US10906899B2 (en) * | 2016-05-10 | 2021-02-02 | Georgia State University Research Foundation, Inc. | Bicyclic fused pyrazole derivatives for the treatment of RSV |
| CA3023922C (en) | 2016-05-10 | 2023-04-18 | Georgia State University Research Foundation, Inc. | Heterocyclic derivatives for the treatment of rsv |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| AR109596A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos pirazolopiridina y sus usos |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| BR112019023109A2 (pt) | 2017-05-04 | 2020-05-26 | Glenmark Pharmaceuticals S.A. | Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo |
| WO2019023448A1 (en) | 2017-07-26 | 2019-01-31 | Emory University | INHIBITORS OF NADPH OXIDASE AND THEIR USE |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| EP3479843A1 (en) | 2017-11-01 | 2019-05-08 | GenKyoTex Suisse SA | Use of nox inhibitors for treatment of cancer |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| DK3755703T3 (da) | 2018-02-20 | 2022-06-27 | Incyte Corp | N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| CN109846900B (zh) * | 2018-05-25 | 2021-07-23 | 四川大学 | 还原型烟酰胺腺嘌呤二核苷酸磷酸在制备抗病毒药物中的用途 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020052738A1 (en) * | 2018-09-11 | 2020-03-19 | F. Hoffmann-La Roche Ag | Pyrazolopyridine amine compounds for the treatment of autoimmune disease |
| WO2020068729A1 (en) | 2018-09-25 | 2020-04-02 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 abd/or fgfr modulators |
| KR20220059480A (ko) | 2019-08-06 | 2022-05-10 | 인사이트 코포레이션 | 고체 형태의 hpk1 억제제 |
| EP4384168A4 (en) * | 2021-08-13 | 2025-07-09 | Univ Georgia State Res Found | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY INFECTIONS INCLUDING RSV |
| US11896719B2 (en) | 2022-01-24 | 2024-02-13 | Calliditas Therapeutics Ab | Pharmaceutical compositions |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3931407A (en) * | 1973-03-01 | 1976-01-06 | American Hoechst Corporation | Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent |
| DE3728278A1 (de) * | 1986-12-17 | 1988-06-23 | Bayer Ag | Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten |
| DE19518082A1 (de) * | 1995-05-17 | 1996-11-21 | Merck Patent Gmbh | 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one |
| US5763496A (en) | 1995-11-27 | 1998-06-09 | The Research Foundation Of State University Of New York | Prevention of atherosclerosis using NADPH oxidase inhibitors |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| WO1998037068A1 (en) * | 1997-02-21 | 1998-08-27 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
| IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
| US7902179B2 (en) | 2001-04-26 | 2011-03-08 | Ajinomoto Co., Inc. | Heterocyclic compounds |
| EP1291017A3 (en) | 2001-09-10 | 2003-07-02 | Warner-Lambert Company | Use of statins to inhibit formation of osteoclasts |
| CA2483306A1 (en) * | 2002-04-23 | 2003-11-06 | Shionogi & Co., Ltd. | Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same |
| WO2004005267A2 (en) | 2002-07-03 | 2004-01-15 | Janssen Pharmaceutica, N.V. | Heteroaryl compounds useful in treating inflammatory disorders |
| CN1774243A (zh) | 2003-02-28 | 2006-05-17 | 霍华德弗洛里实验生理及医药学院 | 治疗组合物 |
| EP1616576A4 (en) | 2003-04-08 | 2010-02-10 | Mitsubishi Tanabe Pharma Corp | SPECIFIC NAD (P) H OXIDASE HEMMER |
| WO2005080378A1 (ja) | 2004-02-24 | 2005-09-01 | Mitsubishi Pharma Corporation | 縮合ピリダジン誘導体 |
| WO2006041874A2 (en) | 2004-10-04 | 2006-04-20 | Myriad Genetics, Inc. | Compounds for alzheimer's disease |
| FR2882654B1 (fr) | 2005-03-01 | 2007-04-27 | Servier Lab | Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques |
| US7759337B2 (en) | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| EP1896134A2 (en) | 2005-06-13 | 2008-03-12 | Rigel Pharmaceuticals, Inc. | Methods and compositions for treating degenerative bone disorders |
| US20070014739A1 (en) | 2005-07-14 | 2007-01-18 | Eldridge Gary R | Compositions and methods for controlling biofilms and bacterial infections |
| DE102005048897A1 (de) * | 2005-10-12 | 2007-04-19 | Sanofi-Aventis Deutschland Gmbh | Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| JP2009532501A (ja) * | 2006-04-04 | 2009-09-10 | ミリアド ジェネティクス， インコーポレイテッド | 疾患および障害のための化合物 |
| EP2002835A1 (en) | 2007-06-04 | 2008-12-17 | GenKyo Tex | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2000176A1 (en) | 2007-06-04 | 2008-12-10 | GenKyo Tex | Tetrahydroindole derivatives as NADPH Oxidase inhibitors |
| WO2009072643A1 (en) | 2007-12-03 | 2009-06-11 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound and use thereof |
| US20090163452A1 (en) | 2007-12-20 | 2009-06-25 | Schwartz Janice B | Compositions and methods for lowering serum cholesterol |
| FR2929276B1 (fr) | 2008-04-01 | 2010-04-23 | Servier Lab | Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2166010A1 (en) * | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166009A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| EP2165707A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2166008A1 (en) | 2008-09-23 | 2010-03-24 | Genkyo Tex Sa | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors |
| EP2305679A1 (en) | 2009-09-28 | 2011-04-06 | GenKyoTex SA | Pyrazoline dione derivatives as nadph oxidase inhibitors |
| WO2011085293A1 (en) | 2010-01-08 | 2011-07-14 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of migraine headaches |
| EP2361912A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| EP2361911A1 (en) | 2010-02-18 | 2011-08-31 | GenKyoTex SA | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors |
| EP2591782A1 (en) | 2011-11-11 | 2013-05-15 | Johann Wolfgang Goethe-Universität | Nadph oxidase 4 inhibitors and use thereof |
-
2007
- 2007-06-04 EP EP07109555A patent/EP2002835A1/en not_active Withdrawn
-
2008
- 2008-03-20 US US12/532,336 patent/US8389518B2/en active Active
- 2008-03-20 SI SI200830863T patent/SI2139477T1/sl unknown
- 2008-03-20 ES ES12187254.3T patent/ES2512491T3/es active Active
- 2008-03-20 PL PL12187254T patent/PL2545918T3/pl unknown
- 2008-03-20 HR HRP20130143AT patent/HRP20130143T1/hr unknown
- 2008-03-20 JP JP2009554036A patent/JP5715340B2/ja active Active
- 2008-03-20 ES ES08718102T patent/ES2398994T3/es active Active
- 2008-03-20 BR BRPI0808824A patent/BRPI0808824B8/pt active IP Right Grant
- 2008-03-20 EP EP08718102A patent/EP2139477B1/en active Active
- 2008-03-20 CA CA2676954A patent/CA2676954C/en active Active
- 2008-03-20 CN CN200880009282.4A patent/CN101686967B/zh active Active
- 2008-03-20 PL PL08718102T patent/PL2139477T3/pl unknown
- 2008-03-20 AU AU2008228186A patent/AU2008228186C1/en active Active
- 2008-03-20 SI SI200831317T patent/SI2545918T1/sl unknown
- 2008-03-20 CN CN201510477495.1A patent/CN105061422B/zh active Active
- 2008-03-20 RS RS20140562A patent/RS53641B1/sr unknown
- 2008-03-20 WO PCT/EP2008/053390 patent/WO2008113856A1/en not_active Ceased
- 2008-03-20 DK DK08718102.0T patent/DK2139477T3/da active
- 2008-03-20 DK DK12187254.3T patent/DK2545918T3/da active
- 2008-03-20 PT PT121872543T patent/PT2545918E/pt unknown
- 2008-03-20 EP EP12187254.3A patent/EP2545918B1/en active Active
- 2008-03-20 RS RS20130060A patent/RS52640B/sr unknown
- 2008-03-20 PT PT87181020T patent/PT2139477E/pt unknown
-
2009
- 2009-09-17 IL IL201009A patent/IL201009A/en active IP Right Grant
-
2013
- 2013-01-04 US US13/734,205 patent/US9073919B2/en active Active
- 2013-01-23 CY CY20131100067T patent/CY1113556T1/el unknown
-
2014
- 2014-10-09 CY CY20141100820T patent/CY1115633T1/el unknown
- 2014-10-23 HR HRP20141029AT patent/HRP20141029T1/hr unknown
-
2015
- 2015-03-13 JP JP2015050104A patent/JP6047189B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021204292B2 (en) | sGC Stimulators | |
| ES2572803T3 (es) | Estimuladores de GCs | |
| HRP20130143T1 (hr) | Derivati pirazolo piridina kao inhibitori nadph oksidaze | |
| RU2326881C2 (ru) | Конденсированные производные азолпиримидина, обладающие свойствами ингибитора фосфатидилинозитол-3-киназы (pi3k) | |
| ES2623491T3 (es) | Estimuladores de GCs | |
| JP5931885B2 (ja) | ＭｅｔＡＰ２阻害剤としてのピロリジノン | |
| JP2012525431A5 (enExample) | ||
| JP2016539144A5 (enExample) | ||
| CA2885645A1 (en) | Sgc stimulators | |
| ES2707323T3 (es) | Diazol lactamas | |
| JP2021527638A (ja) | Ｂ型肝炎カプシドアセンブリモジュレーター | |
| CA2933250A1 (en) | Sgc stimulators | |
| JP5080241B2 (ja) | Ｊｎｋ阻害剤およびスクロスポリンを含んでなる組成物 | |
| JP2006502112A5 (enExample) | ||
| EP3691620A1 (en) | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd | |
| WO2009050242A3 (de) | Heterocyclus-substituierte piperazino-dihydrothienopyrimidine | |
| DK2474543T3 (en) | Therapeutic agent for affective disorders. | |
| JP2011528658A5 (enExample) | ||
| PT702013E (pt) | Imidazopiridinas | |
| CA2961531A1 (en) | Sgc stimulators | |
| RU2011116232A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| CA2818025A1 (en) | Pyridazine derivatives, compositions and methods for treating cognitive impairment | |
| ES2892956T3 (es) | Moduladores alostéricos positivos del receptor muscarínico de acetilcolina M4 | |
| WO2014078377A1 (en) | Methods and compositions for treating schizophrenia | |
| WO2024151465A1 (en) | Protease inhibitors for treating or preventing coronavirus infection |